Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron Vitrasert NDA for CMV filed June 30; collaboration with Roche announced.

Executive Summary

CHIRON VITRASERT OPHTHALMIC IMPLANT NDA REFERENCES ROCHE GANCICLOVIR DMF under an agreement with Hoffmann-La Roche announced July 5. "With the inclusion of ganciclovir [drug master file] reference rights from Roche Bioscience, our filing contains all the information necessary for a rapid FDA review," Chiron said. The company filed an NDA for the ganciclovir ophthalmic implant for treatment of cytomegalovirus retinitis on June 30.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel